Thus, cancer-associated SPOP mutations compromise its substrate recognition and the degradation of an increasing number of known and potential oncoproteins such as DAXX (18,181,182), BRD4 (189,190), MYC (191), the androgen receptor (AR) (192), PD-L1 (193), ERG (194) and Nanog (195,196). This evidence concerns the gene SPOP and cancer.